BSW Wealth Partners Takes Position in Niagen Bioscience, Inc. $NAGE

BSW Wealth Partners bought a new stake in Niagen Bioscience, Inc. (NASDAQ:NAGE) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 85,000 shares of the company’s stock, valued at approximately $793,000. BSW Wealth Partners owned approximately 0.11% of Niagen Bioscience at the end of the most recent quarter.

Separately, Silverberg Bernstein Capital Management LLC acquired a new position in shares of Niagen Bioscience in the 3rd quarter valued at $1,169,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

Insider Activity

In other Niagen Bioscience news, CFO Ozan Pamir purchased 4,465 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The stock was acquired at an average cost of $6.81 per share, with a total value of $30,406.65. Following the completion of the acquisition, the chief financial officer directly owned 7,372 shares of the company’s stock, valued at $50,203.32. This represents a 153.59% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 9.39% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on NAGE. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Wednesday, October 8th. Wall Street Zen downgraded Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 9th. Finally, Canaccord Genuity Group lowered their price objective on Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $14.28.

Niagen Bioscience Price Performance

Shares of NAGE opened at $6.61 on Friday. The company has a market capitalization of $527.54 million, a P/E ratio of 27.54 and a beta of 2.31. Niagen Bioscience, Inc. has a one year low of $5.16 and a one year high of $14.69. The business’s 50 day simple moving average is $6.87 and its 200-day simple moving average is $9.19.

Niagen Bioscience (NASDAQ:NAGE) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. The firm had revenue of $33.99 million during the quarter, compared to the consensus estimate of $31.30 million. Niagen Bioscience had a return on equity of 24.13% and a net margin of 16.38%.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.